BIOSTAR PHARMACEUTICALS, INC.
BIOSTAR PHARMACEUTICALS, INC. (BSPM): 8 pipeline candidates · ~1181 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1180.6 months
0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for BIOSTAR PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$263
Cash
$365K
Quarterly Burn
$1K
Runway
1180.6 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| fluoropyrimidine- | Phase 2/Phase 3 |
| pd-1 inhibitor | Phase 2/Phase 3 |
| utidelone | Phase 2 |
| utidelone capsule 35mg/m2/d bid | Phase 2 |
| utidelone capsule 40mg/m2/d bid | Phase 2 |
| utidelone capsule 50mg/m2/d bid | Phase 2 |
| utidelone capsule 75mg/m2/d qd | Phase 2 |
| xin ao xing oleanolic acid | Approved |
Frequently asked questions
How many drug candidates are in BIOSTAR PHARMACEUTICALS, INC.'s pipeline?
BIOSTAR PHARMACEUTICALS, INC. (BSPM) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIOSTAR PHARMACEUTICALS, INC.'s lead drug candidate?
BIOSTAR PHARMACEUTICALS, INC.'s most advanced tracked candidate is fluoropyrimidine- (Phase 2/Phase 3) for Gastric or Gastroesophageal Junction Adenocarcinoma.
What is BIOSTAR PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIOSTAR PHARMACEUTICALS, INC. has approximately 1180.6 months of cash runway.
What is BIOSTAR PHARMACEUTICALS, INC.'s market capitalization?
BIOSTAR PHARMACEUTICALS, INC.'s market capitalization is approximately $263.
Who is the CEO of BIOSTAR PHARMACEUTICALS, INC.?
Mr. Ronghua Wang Ph.D. is the chief executive officer of BIOSTAR PHARMACEUTICALS, INC. (BSPM).
Get the full picture on BIOSTAR PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.